Drug Combination Details
| General Information of the Combination (ID: C68125) | |||||
|---|---|---|---|---|---|
| Name | Cucurbitacin D NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs. Front Oncol. 2020 Feb 18;10:62. | |||
